women were identified as potentially exposed to ZIKV. Of the 214 (81%) women eligible for ZIKV testing according to CDC guidelines, 12 (5.6%) demonstrated positive results by serology or RNA. The majority of women were returning travelers (83%) spending less than 10 days abroad. While immigrants from ZIKV-affected regions represented only 17% of the entire cohort, these women made up 42% of patients testing positive for ZIKV. In addition, women who tested positive for ZIKV were more likely to have been exposed at a later gestational age (17 vs. 12 wks, p¼0.02) and to report symptoms of illness (25% vs. 7%, p¼0.02) when compared to women with negative testing. Among the ZIKV positive women, two pregnancies were terminated and one neonate, born at 24 weeks, expired after birth. Of the 8 infants born to ZIKV positive mothers, 4 (50%) underwent confirmatory testing; however, among the 21 neonates born to women identified as potentially exposed to ZIKV but did not meet criteria for testing during pregnancy, none underwent testing after birth. CONCLUSIONS: In our cohort, pregnant women infected with ZIKV were more likely to be immigrants, to report symptoms of illness, and to have been exposed at a later gestational age. While there was a high level of accuracy in identifying women eligible for ZIKV testing during pregnancy (81%), uptake of the CDC recommendations for neonatal testing was poor. Resources are needed to improve communication between the state departments of health, obstetricians, pediatricians, and affected families so that at-risk children may be screened and followed closely through development.
22 Group B streptococcus (GBS) colonization and disease among pregnant women: a historical cohort study OBJECTIVES: Maternal GBS colonization is associated with earlyonset neonatal sepsis and extensive efforts are directed to preventing this complication. Less is known regarding the maternal risks of GBS colonization. We seek to provide a modern estimate of the incidence of GBS colonization as well as invasive GBS disease. METHODS: A single center historical cohort study of all births greater than 20 weeks gestation between 2003 and 2015 was performed. Data collection was performed using electronic chart abstraction. GBS colonization status and invasive disease were defined per CDC guidelines. Descriptive statistics were performed to characterize cohorts with and without GBS colonization and invasive GBS disease. Inferential statistics were performed comparing risk of adverse pregnancy outcomes in cohorts with and without GBS colonization. RESULTS: A total of 59,995 deliveries were included for analysis. Overall, 21.6% of the population was GBS colonized. Mean maternal age (SD) was 28.6 (6.2) years and 34% of the population was self-identified African-American and 15% Hispanic. Demographic characteristics and adverse outcomes were compared between those with and without GBS colonization. There are significant differences (p<0.01) with regards to age, race, chronic hypertension, preexisting diabetes, and tobacco use. There were also increased risk of preeclampsia, gestational diabetes, and pyelonephritis in GBS colonized patients and decreased risk of chorioamnionitis and cesarean wound infection. CONCLUSIONS: This modern large cohort demonstrates a GBS colonization rate consistent with older literature. Increased risk of preeclampsia and gestational diabetes may be related to increased systemic inflammation in the setting of GBS colonization. Decreased chorioamnionitis and wound infections is likely secondary to intrapartum GBS prophylaxis in the colonized group.
23 Interest in multipurpose prevention technologies for protection against unintended pregnancy, human immunodeficiency virus and other sexually transmitted infections among women in the united states OBJECTIVES: High rates of sexually transmitted infections (STIs) and unintended pregnancy in the U.S. suggest a role for multipurpose prevention technologies (MPTs) designed to combine contraception and infection prophylaxis into one unified method. This study aims to determine factors associated with interest in MPTs among U.S. women.
METHODS:
We administered a national cross-sectional survey via Amazon's Mechanical Turk, an online task marketplace. Eligibility criteria included female gender, age 18 to 29 years, residence in the U.S., and sexual activity with a male partner in the past three months. 835 completed surveys were suitable for analysis. Bivariable and multivariable logistic regressions were performed to determine factors associated with interest in MPTs. RESULTS: 82.9% of women surveyed were interested in MPTs combining contraception with HIV/STI prevention. More women were interested in MPTs than in contraception (76.3%, p < 0.001) or HIV prophylaxis (68.0%, p < 0.001) alone. In the multivariable model, factors associated with interest in MPTs included oral sex in the past three months (aOR 1.87, 95% CI 1.07, 3.53), recent use of oral contraceptive pills (aOR 1.78, 95% CI 1.08, 2.93), HIV test within the past year (aOR 2.10, 95% CI 1.29, 3.40), and increased STI worry score (aOR 1.98, 95% CI 1.36, 2.86). No use of contraception within the past three months was associated with decreased interest in MPTs (aOR 0.31, 95% CI 0.17, 0.58). HIV risk factors including age, race, and high-risk sexual behaviors were not associated with interest. CONCLUSIONS: Our data are the first to show that young, sexually active, U.S. women are interested in MPTs. Interest was higher for a dual-purpose product designed for prevention of both unintended pregnancy and HIV/STIs than for contraception or HIV prophylaxis alone. Women who recently used protection or evidenced concern for infection were most likely to be interested in such a product. Women reporting unsafe sexual habits were less likely to be interested in MPTs, highlighting the importance of sexual health and HIV/STI prevention education, particularly for those at highest risk. 
